JMJD8 and metastatic malignant neoplasm: Finally, the top ERGs identified in our CRISPR-Cas9 screen (including MBD5 and JMJD8) were significantly more frequently mutated in metastatic cancer cases compared with their nonmetastatic counterparts across 21 different cancer types (Fig. 5N,O), further corroborating the findings of the CRISPR-Cas9 screen that EMT-specific ERGs may be involved in conferring on cancer cells invasiveness and metastatic potential.